Business Context and Reporting Period
This Form 8-K is filed by Intrexon Corporation (not Precigen, Inc.) on September 4, 2015, reporting the completion of the acquisition of Oxitec Limited, a company incorporated in England and Wales, on that same date.
Key Financial Metrics and Transaction Details
The acquisition consideration consisted of:
- Stock Consideration: 1,359,343 shares of Intrexon common stock.
- Cash Consideration: $80.75 million.
Withheld Consideration: A portion of the consideration was withheld at closing and is payable 18 months post-closing, subject to reduction for indemnification claims:
- 480,422 shares of Intrexon common stock.
- Approximately $2.0 million in cash.
The filing text does not provide specific revenue, profit, cash flow, margin, debt, or liquidity metrics for the reporting period, as this is a current report regarding a specific transaction rather than a periodic financial statement.
Material Changes
The primary material change is the expansion of Intrexon's asset base through the full acquisition of Oxitec Limited's issued and to-be-issued share capital. This transaction alters the company's capital structure through the issuance of new shares and the deployment of cash reserves.
Outlook, Risks, and Contingencies
Contingencies: The release of the withheld stock and cash consideration is contingent upon the satisfaction of claims for indemnification made by Intrexon under the Acquisition Agreement over the 18-month period following closing.
Financial Reporting: Intrexon indicated it will file required financial statements and pro forma financial information by amendment no later than 71 calendar days after the filing date of this report.
Investor Verification Checklist
- Verify the total number of Intrexon shares outstanding post-issuance of the 1,359,343 acquisition shares.
- Confirm the impact of the $80.75 million cash outflow on Intrexon's liquidity position.
- Review the full text of the Acquisition Agreement (Exhibit 2.1) for specific indemnification terms that could reduce the final consideration paid to Oxitec sellers.
- Monitor the upcoming amendment filing for pro forma financial information detailing the combined entity's financial position.